BRIEF published on 01/27/2025 at 12:35, 4 months 21 days ago NanoViricides Advances NV-387 to Phase II Clinical Trial NanoViricides NV-387 Clinical Trial Antiviral Drug MPOX Treatment
PRESS RELEASE published on 01/27/2025 at 12:30, 4 months 21 days ago NanoViricides Engages CRO for Phase II Clinical Trial NanoViricides, Inc. engages a Clinical Research Organization for Phase II trial of broad-spectrum antiviral drug NV-387 targeting MPox virus infection. Drug aims to combat viral diseases effectively NanoViricides NV-387 Clinical Trial Antiviral Drug Mpox Virus
BRIEF published on 01/13/2025 at 12:35, 5 months 4 days ago NanoViricides présentera ses avancées antivirales révolutionnaires au Biotech Showcase NanoViricides NV-387 Essais Cliniques Médicaments Antiviraux Vitrine Biotechnologique
BRIEF published on 01/13/2025 at 12:35, 5 months 4 days ago NanoViricides to Present Breakthrough Antiviral Developments at Biotech Showcase NanoViricides NV-387 Biotech Showcase Clinical Trials Antiviral Drugs
PRESS RELEASE published on 01/13/2025 at 12:30, 5 months 4 days ago NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 NanoViricides, Inc. to present Phase II-ready drug NV-387 at Biotech Showcase 2025 in San Francisco, demonstrating broad-spectrum antiviral activity against various infections NV-387 NanoViricides Inc. Antiviral Drug San Francisco Biotech Showcase 2025
BRIEF published on 01/08/2025 at 12:35, 5 months 9 days ago Antiviraux à large spectre : une nécessité face aux multiples menaces virales NanoViricides NV-387 Antiviraux À Large Spectre Virus À ARN Résistance Virale
BRIEF published on 01/08/2025 at 12:35, 5 months 9 days ago Broad-Spectrum Antivirals: A Necessity Amid Multiple Viral Threats NanoViricides NV-387 Broad-spectrum Antivirals RNA Viruses Viral Resistance
PRESS RELEASE published on 01/08/2025 at 12:30, 5 months 9 days ago Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals NanoViricides, Inc. President Dr. Anil Diwan comments on multiple pandemic-causing viruses worldwide, highlighting NV-387's broad-spectrum antiviral capabilities NanoViricides NV-387 Antiviral Broad-spectrum Pandemic
BRIEF published on 12/23/2024 at 12:35, 5 months 25 days ago NanoViricides Positions NV-387 as Key Player Against Bird Flu NanoViricides NV-387 Antiviral Drug H5N1 Virus Bird Flu
BRIEF published on 12/23/2024 at 12:35, 5 months 25 days ago NanoViricides positionne le NV-387 comme un acteur clé dans la lutte contre la grippe aviaire NanoViricides NV-387 Virus H5N1 Médicament Antiviral Grippe Aviaire
Published on 06/17/2025 at 23:00, 1 hour 14 minutes ago New to The Street Signs Backstage ($ BKS) to 12-Part Media Series Covering Music, Sports, and Tokenized Real-World Assets in Entertainment
Published on 06/17/2025 at 23:00, 1 hour 14 minutes ago Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy
Published on 06/17/2025 at 22:10, 2 hours 4 minutes ago Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
Published on 06/17/2025 at 20:00, 4 hours 14 minutes ago PPX Mining Announces Second Debenture Conversion By RIVI
Published on 06/17/2025 at 22:50, 1 hour 23 minutes ago EQS-Adhoc: Verve Group SE: Verve successfully completes a directed share issue of 12,858,000 new shares raising proceeds of approximately SEK 360 million
Published on 06/17/2025 at 22:50, 1 hour 24 minutes ago Verve Group SE (Nordic): Verve successfully completes a directed share issue of 12,858,000 new shares raising proceeds of approximately SEK 360 million
Published on 06/17/2025 at 20:00, 4 hours 14 minutes ago Walor North America Inc. has acquired TSM Corporation from HCI Equity Partners and minority shareholders
Published on 06/17/2025 at 19:49, 4 hours 24 minutes ago EQS-Adhoc: Gerresheimer AG reacts to media reports
Published on 06/17/2025 at 19:22, 4 hours 51 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/17/2025 at 17:45, 6 hours 28 minutes ago EURAZEO COMPLETES MAJORITY INVESTMENT IN MAPAL
Published on 06/17/2025 at 17:45, 6 hours 28 minutes ago EURAZEO FINALISE SON INVESTISSEMENT MAJORITAIRE DANS MAPAL
Published on 06/17/2025 at 17:45, 6 hours 29 minutes ago Succès d’une émission obligataire en Sustainability-Linked Bond de 650 millions d’euros à 7,9 ans
Published on 06/17/2025 at 17:45, 6 hours 29 minutes ago Success of a 650 million euros 7.9-year Sustainability-Linked Bond
